Compass gains on new late-stage trial data for psychedelic therapy in depression

businessinsider

Jul 7, 2026 at 06:30 AM

Compass Pathways (CMPS) shares rose ~8% in premarket trading after announcing positive late-stage trial data for its psychedelic therapy COMP360. The 26-week results from the Phase 3 COMP006 trial confirmed rapid onset and durable efficacy for treatment-resistant depression, with no new safety issues. A second dose showed improved clinical benefit over a single dose. The company expects to conclude its rolling New Drug Application submission in Q4 and aims for an H1 2027 launch, pending FDA approval.

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.